Showing posts with label modified oligos. Show all posts
Showing posts with label modified oligos. Show all posts
Tuesday, May 17, 2011
DNA/Constrained Nucleotide Oligonucleotides Hybridized
Bio-Synthesis - the world leader in custom services since 1984.With the industry growing so rapidly, there are "young" companies sprouting all over the place. Many of these same companies are not successful and do not last very long. Bio-Synthesis has been the world leader in custom services since our inception in 1984. Over two decades of the highest quality of products, coupled with fast turnaround time and affordability has enabled BSI to stand in no one else's shadow.
Constrained Nucleotide Oligonucleotide
Custom Constrained Nucleotide Oligonucleotide synthesis High quality Custom Constrained Nucleotide Oligonucleotides are available for a variety of different specialty applications and innovative products.
Oligonucleotide Synthesis
It is the non-biological, chemical synthesis of defined short sequences of nucleic acids. It is extremely useful in laboratory procedures covering a wide range of molecular biology applications. Automated synthesizers allow the synthesis of oligonucleotides up to 160 to 200 bases.
Modified Oligos
Modified oligos terminated with the 5'-Thiol-Modifier C6 is shipped with the trityl protecting group still attached to the sulfur. In order to free the thiol group for use removes the trityl group and reduces the sulfur. Oligonucleotides terminated with the 5'-Thiol-Modifier C6 SS (Disulfide) will need to be reduced before use.
Tuesday, July 22, 2008
Antisense Technology
At Bio-Synthesis, we offer discovery scale synthesis to mid-scale multi gram quantities for clinical diagnostic applications, in addition to the synthesis of these modified oligos, we routinely assist customers in the design of the oligos that are particularly suited to their applications.
Antisense therapy
Antisense therapy is a form of treatment for genetic disorders or infections. When the genetic sequence of a particular gene is known to be causative of a particular disease, it is possible to synthesize a strand of nucleic acid (DNA, RNA or a chemical analogue) that will bind to the messenger RNA (mRNA) produced by that gene and inactivate it, effectively turning that gene "off". This is because mRNA has to be single stranded for it to be translated. The goal of antisense applications is to shut down activity of a defined gene by blocking transcription or translation within cells. Oligonucleotides for antisense assays must be nuclease resistant against cellular nucleases, must be able to cross cellular membranes and must inherit both high binding affinity and specificity for the target sequence. In many cases, they also must have the ability to induce RNase H cleavage.
Antisense DNA
Antisense molecules interact with complementary strands of nucleic acids, modifying expression of genes. Some regions within a double strand of DNA code for genes, which are usually instructions specifying the order of amino acids in a protein along with regulatory sequences, splicing sites, non coding introns and other complicating details. For a cell to use this information, one strand of the DNA serves as a template for the synthesis of a complementary strand of RNA. The stability of the RNA-DNA duplex in term of hybrization and half-life is crucial to successful gene inhibition. Vigorous research activity in the area of nucleic acid chemistry has been devoted in developing novel base analgos that are resistant to degradation and that possess strong hybridization properties. This includes the classical phosphorothioate linkages, propyne analogs and the latest lock nucleic acid (LNA) base analogs, and peptide nucleic acid (PNA).
Antisense mRNA
Antisense mRNA is an mRNA transcript that is complementary to endogenous mRNA. In other words, it is a non-coding strand complementary to the coding sequence of mRNA; this is similar to negative-sense viral RNA. Introducing a transgenic coding for antisense mRNA is a technique used to block expression of a gene of interest. Radioactively-labeled antisense mRNA can be used to show the level of transcription of genes in various cell types. Some alternative antisense structural types are being experimentally applied as antisense therapy, with at least one antisense therapy approved for use in humans.
Antisense therapy
Antisense therapy is a form of treatment for genetic disorders or infections. When the genetic sequence of a particular gene is known to be causative of a particular disease, it is possible to synthesize a strand of nucleic acid (DNA, RNA or a chemical analogue) that will bind to the messenger RNA (mRNA) produced by that gene and inactivate it, effectively turning that gene "off". This is because mRNA has to be single stranded for it to be translated. The goal of antisense applications is to shut down activity of a defined gene by blocking transcription or translation within cells. Oligonucleotides for antisense assays must be nuclease resistant against cellular nucleases, must be able to cross cellular membranes and must inherit both high binding affinity and specificity for the target sequence. In many cases, they also must have the ability to induce RNase H cleavage.
Antisense DNA
Antisense molecules interact with complementary strands of nucleic acids, modifying expression of genes. Some regions within a double strand of DNA code for genes, which are usually instructions specifying the order of amino acids in a protein along with regulatory sequences, splicing sites, non coding introns and other complicating details. For a cell to use this information, one strand of the DNA serves as a template for the synthesis of a complementary strand of RNA. The stability of the RNA-DNA duplex in term of hybrization and half-life is crucial to successful gene inhibition. Vigorous research activity in the area of nucleic acid chemistry has been devoted in developing novel base analgos that are resistant to degradation and that possess strong hybridization properties. This includes the classical phosphorothioate linkages, propyne analogs and the latest lock nucleic acid (LNA) base analogs, and peptide nucleic acid (PNA).
Antisense mRNA
Antisense mRNA is an mRNA transcript that is complementary to endogenous mRNA. In other words, it is a non-coding strand complementary to the coding sequence of mRNA; this is similar to negative-sense viral RNA. Introducing a transgenic coding for antisense mRNA is a technique used to block expression of a gene of interest. Radioactively-labeled antisense mRNA can be used to show the level of transcription of genes in various cell types. Some alternative antisense structural types are being experimentally applied as antisense therapy, with at least one antisense therapy approved for use in humans.
Subscribe to:
Posts (Atom)